Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have lost 32.5 percent of their value since the beginning of the year. However, over the third quarter, the stock has recuperated more than 12.6 percent, and the Vetr crowd seems to believe the rebound will continue. This is evidenced by its average price target of $146.84, which implies an upside potential of almost 13.15 percent.
Seeking to better reflect this upside potential, the Vetr community decided to upgrade its rating on shares of Alexion on Friday, from four stars (Buy) to 4.5 stars (Strong Buy) — out of a possible five-star rating.
Finally, it should be noted that, in accordance with the new rating, 87 percent of the crowd’s ratings are bullish.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email firstname.lastname@example.org with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.
Latest Ratings for ALXN
|Dec 2016||Oppenheimer||Initiates Coverage On||Perform|
|Dec 2016||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.